Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide...
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
About this item
Full title
Author / Creator
Ng, Yuen Lam Dora , Ramberger, Evelyn , Bohl, Stephan R. , Dolnik, Anna , Steinebach, Christian , Conrad, Theresia , Müller, Sina , Popp, Oliver , Kull, Miriam , Haji, Mohamed , Gütschow, Michael , Döhner, Hartmut , Walther, Wolfgang , Keller, Ulrich , Bullinger, Lars , Mertins, Philipp and Krönke, Jan
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are highly effective treatments for multiple myeloma. However, virtually all patients eventually relapse due to acquired drug resistance with resistance-causing genetic alterations being found only in a small subset of cases. To identify non-genetic mechanisms of drug resistance, we h...
Alternative Titles
Full title
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d4504678ee754ca4b1b981178e24fb56
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d4504678ee754ca4b1b981178e24fb56
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-022-28515-1
